- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
August 9, 2022Robins Kaplan Recognized in The National Law Journal’s Top 100 Verdicts List For 2021
-
August 1, 2022Marc Betinsky Appointed to Magistrate Judge Merit Selection Panel
-
July 28, 2022Jake Holdreith, Robins Kaplan Shortlisted For LMG Life Sciences Awards
-
August 18, 2022Annual Robins Kaplan MAJ Welcome Reception
-
September 9, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
September 10, 2022Children’s Theatre Company 2022 Curtain Call Ball
-
Second QuarterANDA Approvals
-
Second QuarterGeneric Launches
-
July 19, 2022Briefly: What to do with a Reverse and Remand
-
August 10, 2022Crypto Crash Takes $1B Bite Out of Coinbase in Q2
-
August 9, 2022SoftBank Hit With $20+ Billion Quarterly Loss as Tech Investments Falter
-
August 5, 2022All Eyes on July Jobs Report Following Fed Rate Hikes
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Caught between a Rock and a Hard Place:
Patenting in the Life Sciences and the Written Description Requirement
July 1, 2019
Regardless of whether a life science company is a biotech start-up or a pharmaceutical giant, its patents are the keys to the kingdom.1 In the post-AIA, “first-to-file” world, quickly filing a patent application is more critical than ever.2 Rushing to file, though, comes with real risk. Applicants seeking patents on emerging life science technologies, like gene-editing, immunotherapy, and RNA interference, often face written description rejections at the Patent Office.3 Further, even when an inventor successfully obtains claims based on an early filing, those patents may not survive a written description challenge brought by a competitor.4
Originally Published on the AIPLA website in connection with the 2019 Spring Meeting
1 Houldsworth, A., Pharma Patent Owners in the US are under Pressure Like They Have Never Been Before, IAM (Nov. 26,
2018), https://www.iam-media.com/law-policy/us-pharma-patent-owners-under-pressure-never.
2 See Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., No. 17-1229, slip op. at 1 (U.S. Jan. 22, 2019) (explaining that the meaning of “on-sale” was not altered by the America Invents Act (“AIA”), and that even a “secret sale” may invalidate a patent); 35 U.S.C. 102(a)(1), (2) (setting forth the requirements for novelty under the AIA by reference to effective filing dates).
3 See Application No. 15/316,792, Improved T Cell Compositions, Final Rejection dated Nov. 14, 2018 at 12-13 (rejecting claims for the transduction of T cells in the presence of a PI3K inhibitor because the specification only supports exposing T cells to the inhibitor during the activation or stimulation phases); Application No. 13/842,859, Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription, Non-Final Rejection dated Sept. 15, 2015 at 4 (rejecting claims to a modified Cas9 protein that cleaves only one strand of DNA because the claims read on a broad genus of modifications and the specification did not sufficiently describe a representative number of modifications); Application No.
10/832,432, RNA Interference Mediating Small RNA Molecules, Applicant Remarks dated Oct. 25, 2005 at 7 (arguing that the disclosure of an RNA strand that is 19-25 nucleotides in length, with one, 3’ nucleotide overhang clearly encompasses a claimed, double stranded RNA that is 16-22 nucleotides in length).
4 See, e.g., FWP IP Aps v. Biogen MA, Inc., No. 2017-2019, 2018 U.S. App. LEXIS 29943 (Fed. Cir. Oct. 24, 2018); Otonomy, Inc. v. Auris Med., AG, 2017-1850, 2017-1880, 2018 U.S. App. LEXIS 21569 (Fed. Cir. Aug. 1, 2018).
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Sharon E. Roberg-Perez, Ph.D.
Partner
Christopher A. Pinahs
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.